AGIO — Agios Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.66bn
- $2.09bn
- $26.82m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -411 | -327 | 1,605 | -232 | -352 |
Depreciation | |||||
Non-Cash Items | 78.8 | 97.7 | -1,984 | -69.8 | 68.5 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -46 | -71 | -36.8 | -16.4 | -19.1 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -371 | -291 | -407 | -309 | -296 |
Capital Expenditures | -12.2 | -14.9 | -5.74 | -4.88 | -0.999 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 104 | 90.7 | 1,255 | 248 | 241 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 91.4 | 75.7 | 1,249 | 243 | 240 |
Financing Cash Flow Items | 0 | 251 | 0 | 0 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 290 | 262 | -766 | 2.35 | 5.43 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 10.4 | 46.5 | 75.7 | -63.9 | -51.1 |